The Asia-Pacific body mass index classification and new-onset chronic kidney disease in non-diabetic Japanese adults: A community-based longitudinal study from 1998 to 2023

Authors' names and affiliations

Yukari Okawa[1,2], Toshiharu Mitsuhashi[3], and Toshihide Tsuda[4]

[1]Department of Public Health and Welfare, Zentsuji City Hall, 2-1-1 Bunkyo-cho, Zentsuji, Kagawa 765-8503, Japan

[2]Clinical Research Institute, Ohara HealthCare Foundation, 1-1-1 Miwa, Kurashiki, Okayama 710-8602, Japan

[3]Center for Innovative Clinical Medicine, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan

[4]Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan

Corresponding author

Yukari Okawa

Department of Public Health and Welfare, Zentsuji City Hall, 2-1-1 Bunkyo-cho, Zentsuji, Kagawa 765-8503, Japan

https://orcid.org/0000-0002-1704-6609

Tel. +81 877 63 6308

Fax. +81 877 63 6368

E-mail okw3923@gmail.com

Abstract

Background/Objectives

Obesity is a risk factor for chronic kidney disease (CKD) in Asians. The Asia-Pacific body mass index (BMI) classification sets lower obesity cutoffs than the conventional BMI classification for all races, generally reflecting the lower BMIs in Asians. This longitudinal study evaluated the association between BMI, as classified by the Asia-Pacific BMI system, and CKD development in non-diabetic Asian adults.

Methods

A population-based longitudinal study (1998–2023) was conducted in non-diabetic Japanese adults (hemoglobin A1c < 6.5%) in Zentsuji City (Kagawa Prefecture, Japan). The generalized gamma model was used to assess the relationship between time-varying BMI categories and CKD development, stratified by sex. CKD was defined as an estimated glomerular filtration rate of <60 mL/min/1.73 m^2. BMI was calculated as weight (kg) divided by the square of height (m^2) and categorized per the Asia-Pacific classification as overweight (23.0–24.9 kg/m^2), obesity class I (25.0–29.9 kg/m^2), and obesity class II (≥30.0 kg/m^2).

Results

CKD developed in 34.2% of 3,098 men and 34.8% of 4,391 women. The mean follow-up times were 7.41 years for men and 8.25 years for women. During follow-up, the BMI distributions for men were 5.0% underweight, 43.3% normal weight, 25.6% overweight, 24.1% obesity class I, and 2.0% obesity class II; those for women were 7.7%, 50.5%, 20.5%, 18.3%, and 2.9%, respectively. Compared with normal weight, obesity class I was associated with a 6% (95% confidence interval [CI]: 2%–10%) shorter time to CKD onset in men and 5% (95% CI: 2%–7%) in women. In both sexes, obesity class II showed shorter survival times than normal weight by point estimates, although all 95% CIs crossed the null value.

Conclusions

Obesity, as classified by the Asia-Pacific BMI system, shortened the time to CKD onset in non-diabetic Asians. The conventional BMI cutoff for obesity (≥30.0 kg/m^2) may be too high to identify CKD risk in this population. The findings of this study may be useful for public health professionals in designing interventions to prevent CKD.

Keywords

Body mass index; Chronic kidney disease; East Asian; Longitudinal studies; Risk factors

Introduction

Obesity is a well-known risk factor for developing chronic kidney disease (CKD)[1]. Obesity also harms Asian populations, with the risk for CKD onset being 1.13 times higher in men (95% confidence interval [CI]: 1.06–1.20) and 1.02 times higher in women (95% CI: 0.97–1.07) compared with individuals of normal weight[2]. However, the body mass index (BMI) classification for defining obesity in Asians has been a persistent debate, with many experts arguing that the conventional threshold (BMI ≥30.0 kg/m^2) is too high. This is because Asians typically have lower BMI but higher body fat percentage than Whites[3]. These racial differences in body composition are problematic when considering the relationship between BMI and CKD onset because higher body fat elevates the risk of CKD[4]. Thus, a BMI classification system with a lower cutoff might better reflect the relationship between obesity and CKD onset in Asian populations.

In 2000, the World Health Organization Western Pacific Region introduced the Asia-Pacific BMI classification (Asia-Pacific classification) for Asian adults[5]. This classification uses a lower BMI cutoff than the conventional World Health Organization BMI classification (conventional classification), which is applied across all races[6]. Follow-up studies utilizing the Asia-Pacific classification may help establish more accurate BMI targets for CKD prevention in Asians, but such studies remain limited.

Furthermore, diabetes complicates the relationship between obesity and CKD development[7]. A previous meta-analysis among Asians showed that obesity was associated with a 1.05-fold higher risk (95% CI: 1.01–1.10) of developing CKD in the diabetic population and a 1.06-fold higher risk (95% CI: 0.98–1.15) in the non-diabetic population compared with individuals of normal weight[2]. Several follow-up studies have statistically adjusted for prevalent diabetes or glycemic control status (e.g., fasting blood sugar levels) to minimize the confounding effect of diabetes[8–11]. However, diabetes-induced biases may remain because diabetes increases the risk of various factors that cause selection bias (e.g., coronary heart disease, ischemic stroke, and death)[12,13]. Therefore, longitudinal studies evaluating the relationship between obesity and the development of CKD in non-diabetic populations are important.

A previous cohort study of non-diabetic Japanese adults, the Ibaraki Prefecture Health Study (IPHS), revealed that BMI categories of ≥23.0 kg/m^2 for men and ≥27.0 kg/m^2 for women were associated with an elevated risk of CKD compared with the reference group[14,15]. However, this study independently categorized BMI into seven finer groups: <18.5, 18.5–20.9, 21.0–22.9 (reference), 23.0–24.9, 25.0–26.9, 27.0–29.9, and ≥30.0 kg/m^2. Therefore, further follow-up studies using BMI categories standardized for Asians are needed to investigate the relationship between obesity and CKD onset in Asian populations[14].

Based on the above, this longitudinal study investigated the relationship between obesity in the Asia-Pacific classification and the subsequent development of CKD in non-diabetic Japanese adults. By focusing on

BMI thresholds specific to the Asian population, this study aims to address an important gap in CKD risk assessment.

Materials and methods

Data source

This study was a secondary data analysis using anonymized annual health checkup data from Zentsuji City (Kagawa Prefecture, Japan) from 6 April 1998 to 19 April 2023. As of 1 April 2023, the city had a population of 30,431 (49.7% male), with 38.1% of citizens aged ≥60 years[16]. The city database used in previous studies was used for data extraction[17–20]. Data extraction was conducted on 6 July 2023.

All citizens aged ≥40 years were eligible to receive a health checkup once every fiscal year, with participation being voluntary. Participants were free to join or leave the study at any time by choosing whether to undergo checkups. In fiscal years 1998 and 1999, younger citizens aged 34–39 years were also included on a trial basis to promote health awareness among younger populations. Over the years, approximately 30%–40% of the eligible population participated in the checkups[16]. No sampling procedures were implemented in this study.

During the checkups, the participants underwent anthropometric measurements, blood pressure tests, blood tests, and urine dipstick tests, and they completed a questionnaire regarding their lifestyle (e.g., alcohol intake, smoking status, medication use, and dietary and exercise habits)[21]. The checkups were conducted following the protocol established by the Ministry of Health, Labour and Welfare (MHLW), and all items were measured as specified in the protocol[21]. The checkups did not require participants to fast; therefore, they included both fasting and non-fasting individuals. Data on the participants' last meal were not available.

Study participants

This study evaluated the relationship between BMI and the development of CKD in non-diabetic Japanese adults. As such, it included all non-diabetic Japanese adults who underwent their first checkup between 1998 and 2023, were free of CKD at study entry, and had follow-up data to confirm the onset of CKD.

The following exclusion criteria were applied: non-Japanese individuals, individuals with missing exposure and/or outcome data, individuals with prevalent CKD and/or diabetes at study entry, individuals with missing hemoglobin A1c (HbA1c) values, individuals with prevalent diabetes at study entry, and individuals with only one observation (**Figure 1**). Participants who developed diabetes (HbA1c ≥ 6.5%) during follow-up were treated as right-censored[22].

Variables

Exposure: BMI

The exposure variable was obesity, defined using BMI (calculated as weight in kilograms divided by height in meters squared) according to the Asia-Pacific classification: underweight (<18.5 kg/m^2), normal weight (18.5–22.9 kg/m^2), overweight (23.0–24.9 kg/m^2), obesity class I (25.0–29.9 kg/m^2), and obesity class II (≥30.0 kg/m^2)[5]. Obesity class II was categorized separately to assess its impact on the development of CKD in people with severe obesity and to avoid overestimating the effects of obesity class I by misattributing them to this category.

In this analysis, BMI classification was treated as a time-varying variable.

Outcome: CKD onset

The outcome variable was CKD onset, defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m[21]. Because this study exclusively included Japanese participants, eGFR was calculated using the three-variable revised Japanese equation: eGFR (mL/min/1.73m^2) = 194 × serum creatinine (mg/dL)$^{-1.094}$ × age (years)$^{-0.287}$ (× 0.739, if female)[23]. Serum creatinine values were measured in mg/dL to two decimal places using the enzymatic method. Other information useful for determining CKD prevalence, such as definitive diagnoses by physicians, was unavailable and could not be included in this analysis[21].

Other covariates

Sex was defined based on the participants' physical characteristics at birth (male/female). Age (34–59 [reference]/60–69/70–100 years), self-reported alcohol intake (non- or seldom-drinker [reference]/drinker), self-reported smoking status (non- or ex-smoker [reference]/smoker), hypertension (no [reference]/yes), dyslipidemia (no [reference]/yes), HbA1c value (%), and eight residential districts (East [reference]/West/Central/South/Fudeoka/Tatsukawa/Yogita/Yoshiwara) were included as covariates for adjustment[1,2,24].

Hypertension was defined as systolic blood pressure of ≥130 mmHg and/or diastolic blood pressure of ≥80 mmHg[25]. Dyslipidemia was defined as serum low-density lipoprotein cholesterol of ≥140 mg/dL, serum high-density lipoprotein cholesterol of <40 mg/dL, and/or serum triglycerides of ≥150 mg/dL[26]. HbA1c was reported using Japan Diabetes Society (JDS) units from 1998 to 2012 and National Glycohemoglobin Standardization Program (NGSP) units from 2013 to 2023[27,28]. HbA1c levels were standardized to NGSP values using the officially certified equation: $HbA1c_{NGSP}$ (%) = 1.02 × $HbA1c_{JDS}$ (%) + 0.25[29]. Neighborhood indicators (e.g., food quality and availability) have been reported to be associated with obesity, diabetes, and possibly

CKD[24]. Therefore, to reduce the potential impact of the participants' residential locations within the city, the district of residence was treated as a covariate.

This study had a substantial percentage of missing self-reported information (>50%) on medication use, dietary habits, and exercise habits, primarily due to changes in the questionnaire created by the MHLW[21]. A question regarding such information was added in 2012, but the question was either removed or modified in 2020 for older people aged ≥75 years[21]. To avoid age-related bias caused by this imbalance, these variables were excluded from the analysis.

Statistical analysis

All analyses were conducted separately by sex. Participants' characteristics were summarized by BMI class. Person-years at risk were calculated from the date of the first visit to the date of CKD or diabetes onset, or the end of the last visit during the follow-up period. Participant demographics during follow-up were expressed as numbers of patients with CKD onset, total person-years at risk, and incidence rate per 1,000 person-years.

We created Kaplan–Meier curves by the Asia-Pacific classification separately by sex. The proportional hazards assumption was violated as assessed by log–log plots and Schoenfeld residuals[30]. Therefore, the generalized gamma model was selected for the analysis based on the Akaike and Bayesian information criteria[30–33]. The time ratio and its 95% CI were used measures of the exposure effect on the outcome of interest. For example, a time ratio of 0.9 signified a 10% shorter survival time to CKD onset compared with the reference group.

Three adjusted models were constructed in addition to the crude model. Model 1 adjusted for age category. Model 2 further adjusted for self-reported alcohol intake and smoking status. Model 3 additionally adjusted for hypertension, dyslipidemia, HbA1c value, and residential district. To stabilize the models, a multiplicative term (BMI category × variable) was added to Models 1–3 if an interaction effect was observed between the BMI category and the following variables: age category, self-reported alcohol intake, self-reported smoking status, hypertension, dyslipidemia, or HbA1c values.

Because of the voluntary nature of the checkup, missing values were observed for several variables: self-reported alcohol intake (missing in 34.0% of men and 32.7% of women), self-reported smoking status (missing in 31.1% of men and 30.4% of women), hypertension (no missing data in men; missing in 0.02% of women), dyslipidemia (missing in 19.2% of men and 27.0% of women), and residential district (missing in 1.33% of men and 1.42% of women)[21]. Missing measurements were complemented using multiple imputation with chained equations, generating 40 imputations[34,35]. Binary variables and categorical variables

were imputed using logistic regression and multinomial logistic regression, respectively. Only the imputed results were presented because missing measurements were assumed to be missing at random.

We restricted the presentation to the results for the main exposure variable to avoid the Table 2 fallacy[36]. A two-tailed p-value of <0.05 was considered statistically significant. All statistical analyses were performed using Stata/MP 16.1 (StataCorp, College Station, TX, USA). A participant flowchart was created in Python 3.11.10[37]. This study adhered to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines[38].

Sensitivity analyses

Three sensitivity analyses were conducted in this study. First, the conventional classification (underweight [<18.5 kg/m^2], normal weight [18.5–24.9 kg/m^2], overweight [25.0–29.9 kg/m^2], obesity class I [30.0–34.9 kg/m^2], obesity class II [35.0–39.9 kg/m^2], and obesity class III [≥40.0 kg/m^2]) was used as the exposure variable[6]. Because of the small number of participants with a BMI of ≥30.0 kg/m^2, obesity classes I–III were combined into a single obesity category.

Second, to minimize the possibility of reverse causation, participants who developed CKD at the second observation were excluded. Third, to address the potential for temporary abnormal eGFR values, a stringent definition of CKD was applied. CKD was defined as two or more consecutive observations of eGFR <60 mL/min/1.73 m^2. Given the use of annual checkup data, the duration of renal dysfunction in this stringent CKD definition was equal to or longer than the KDIGO definition of CKD, which requires a duration of ≥3 months[1].

Results

Main analysis

Of 6,309 men and 9,192 women (mean age at study entry: 70.0 years for men, 68.3 years for women), 3,098 men and 4,391 women (mean age at study entry: 59.0 years for men, 62.1 years for women) were included in the final cohort (**Figure 1**). The mean follow-up time was slightly longer for women (8.25 years) than for men (7.41 years).

The participants' characteristics by the Asia-Pacific BMI classification are presented in **Table 1** for men and **Table 2** for women. For both sexes, obesity class II had the shortest follow-up time, accounting for <3% of the total follow-up time. After the follow-up, 34.2% of men and 34.8% of women had developed CKD. Kaplan–Meier curves stratified by the Asia-Pacific classification, separately by sex, are provided in **Figure 2**. **Table 3** shows the results of the main analysis. Similar results were observed for both sexes, with obesity class I associated with an approximately 5% shorter survival time to CKD onset compared with normal weight.

For men, obesity class II had the shortest survival time to CKD onset, with a point estimate of 8%, but the 95% CIs included 1 in all models. For women in obesity class II, the results were nearly null.

For reference, using the combined BMI categories of the top two categories (obesity class I and II) as a single obesity category yielded results similar to those of the main analysis: the adjusted time ratios (95% CIs) of overweight and obesity were 0.97 (0.94–1.01) and 0.94 (0.90–0.97) for men and 1.00 (0.97–1.03) and 0.95 (0.93–0.98) for women.

Sensitivity analyses

First sensitivity analysis: The conventional classification

Using the conventional classification, more participants (men: 68.9%, women: 71.0%) were classified as normal weight than in the Asia-Pacific classification (men: 43.3%, women: 50.6%) (**Tables 1 and 2**)[6]. The estimation results were similar for a BMI of ≥30.0 kg/m^2 ("obesity class II" in the Asia-Pacific classification and "obesity" in the conventional classification), showing shorter survival to CKD development in higher BMI categories (**Tables 3 and S1**)[5,6].

Second sensitivity analysis: Reverse causation

The second sensitivity analysis aimed to minimize reverse causation by excluding participants who developed CKD at the second observation, resulting in 2,723 men and 3,832 women remaining in the cohort. The mean age at study entry was higher for men (61.4 years) and lower for women (58.3 years) compared with the main analysis. The mean follow-up period was 8.14 years for men and 9.14 years for women, slightly longer than in the main analysis (**Tables 1 and 2**). The distribution of follow-up time by BMI category was similar to that of the main analysis.

After the follow-up period, 25.1% of men and 25.2% of women had developed CKD, lower than in the main analysis. Most estimation results were consistent with those of the main analysis; however, the point estimates of survival for obesity class II were longer in men and shorter in women compared with the main analysis (**Tables 3 and S2**).

Third sensitivity analysis: Stringent definition of CKD

To minimize variability in eGFR measurements, a stringent definition of CKD requiring two consecutive observations of eGFR <60 mL/min/1.73 m^2 was applied (**Table S3**). Compared with the main analysis (**Tables 1 and 2**), more participants (men: 3,380; women: 4,963) remained in the final cohort, the mean follow-up time was longer (men: 8.13 years; women: 9.29 years), the mean age at study entry was higher for men (62.6

years) and lower for women (59.6 years), and fewer participants developed CKD (men: 20.7%; women: 21.1%).

For men, point estimates for higher BMI categories were similar to those in the main analysis (**Table 3**), including obesity class II, which had the shortest follow-up period. For women, convergence errors were observed in Model 3. The results of Model 2 for women were similar to those of Model 2 in the main analysis.

Discussion

Main analysis

In this population-based longitudinal study (1998–2023) of non-diabetic Japanese adults, obesity class I in the Asia-Pacific classification was associated with earlier CKD onset. Although the 95% CIs for overweight and obesity class II included 1 in all models, the point estimates suggested a dose–response relationship, particularly in men (**Table 3**).

These findings partly align with those of the previous non-diabetic Japanese cohort study from the IPHS[14,15]. Similar to our study, the IPHS demonstrated a dose–response relationship between BMI and CKD onset: CKD risk was higher in BMI categories 23.0–24.9, 25.0–26.9, 27.0–29.9, and ≥30.0 kg/m^2 in men and 27.0–29.9 and ≥30.0 kg/m^2 in women compared with the BMI category 21.0–22.9 kg/m^2. However, our study showed a dose–response relationship by point estimates in men but not in women.

Three factors may explain this discrepancy. First, the sample size in this study (n = 7,489) was smaller than that of the IPHS (n = 89,760)[14], potentially resulting in insufficient power to detect a true effect in the small proportion of participants with obesity class II (<3% of the total population). Second, our participants were older (range: 34–100 years) than those in the IPHS (range: 40–79 years). To mitigate bias, adjustments for age were made to reduce the likelihood of over- or underestimation caused by older adults' tendency to have a lower BMI[39]. Nonetheless, the generalizability of our findings to populations with different age distributions remains limited. Third, the observational period in this study (1998–2023) was longer than that of the IPHS (1993–2006). A longer follow-up period may decrease participants' susceptibility to outcomes over time[40]. Specifically, the extended observational period in our study likely introduced more selection bias compared with the IPHS, contributing to an underestimation of results[40].

In this study, men had a shorter survival time to CKD onset than women with the same BMI (**Tables 1 and 2**). This trend was consistent with the findings from the IPHS and can be partly attributed to biological and physiological differences between sexes[14]. Higher muscle mass in men than in women may result in systematic errors in estimation of the GFR because higher muscle mass can be misclassified as a lower eGFR[41,42]. Consequently, the results are likely to be overestimated in men. However, most participants in this study were older adults (i.e., those aged ≥70 years), who tend to have a lower BMI and muscle mass, leading

to underestimation (**Tables 1 and 2**)[39,41]. Therefore, the sex-related overestimation is likely attenuated. Furthermore, as noted above, this study had large random errors in obesity class II, which accounted for the shortest follow-up time (<3% of the total follow-up period) (**Tables 1 and 2**). As a result, unmeasured factors may have had a greater impact on the results of this study, especially in obesity class II.

Sensitivity analyses

First sensitivity analysis: Conventional classification

Table S1 presents the results using the conventional BMI classification as the exposure variable[6]. Obesity had the lowest point estimates for men and an almost null value for women, with all 95% CIs crossing 1. Compared with the findings of the main analysis, overweight (which corresponds to obesity class I in the Asia-Pacific classification) was associated with shorter survival to CKD onset. These results suggest that the conventional BMI cutoff of ≥30.0 kg/m^2 for obesity may be too high to act as a risk factor for CKD in non-diabetic Japanese adult populations.

Second sensitivity analysis: Reverse causation

Table S2 shows the results after minimizing the possibility of reverse causation by excluding participants who developed CKD at the second observation. For all BMI categories below 30.0 kg/m^2, the results followed a trend similar to that observed in the main analysis (**Table 3**), suggesting no clear evidence of reverse causation between these BMI categories and CKD onset.

However, a weak inverse association was observed in the BMI ≥30.0 kg/m^2 category. As noted earlier, evaluating the relationship between BMI ≥30.0 kg/m^2 and CKD onset was hindered by reduced statistical power. Consequently, a type II error may have occurred in this category, suggesting the possibility of a dose–response relationship between BMI and CKD development in this analysis.

Third sensitivity analysis: Stringent definition of CKD

Using the stringent CKD definition, where two consecutive observations of eGFR <60 mL/min/1.73 m^2 were required to define CKD, the results (**Table S3**) showed trends similar to the main analysis in Models 1 and 2 (**Table 3**). Compared with the main analysis (men: 1,059; women: 1,526), fewer participants developed CKD (men: 700; women: 1,049), which caused a convergence error in Model 3.

Strengths and limitations

A strength of this study was its use of the Asia-Pacific BMI classification to evaluate the impact of elevated BMI on the development of CKD in non-diabetic monoracial Asian men and women, using longitudinal data with a relatively long follow-up period (1998–2023).

However, several limitations must be noted. First, because East Asians tend to have a lower BMI than Westerners, the number of participants in the highest BMI category (≥30.0 kg/m^2) was low in this study, and the relationship between BMI and subsequent development of CKD could not be fully assessed[3,43].

Second, a high BMI does not necessarily equate to obesity. The BMI is calculated based on weight and height and does not account for body composition, such as body fat percentage. When obesity is defined as body fat percentages of ≥25% for men and ≥35% for women in an Asian population, detecting obesity using a BMI of ≥30.0 kg/m^2 has high specificity (men: 97.3%, women: 95.0%) but low sensitivity (men: 6.7%, women: 13.4%)[44]. Therefore, a BMI cutoff of ≥30.0 kg/m^2 misses most participants with high body fat, resulting in misclassification and underestimation in the highest BMI category[3,43].

Third, the exact date of CKD onset could not be determined—a major and unresolved limitation of cohort studies that are based on annual checkup data and in which participants can decide when to be screened. These factors lead to interval censoring, which requires highly complex statistical models to address[45].

Fourth, measurement errors in renal function may have occurred. Because this study was a secondary data analysis, inulin clearance values (the gold standard for assessing GFR) were unavailable for evaluation[1]. Instead, we used serum creatinine to estimate GFR using the three-variable revised Japanese equation, which is more accurate than the Modification of Diet in Renal Disease equations[23]. Furthermore, other useful indicators for detecting CKD (e.g., cystatin C) were also unavailable in this study[1]. The inability to combine such variables to define CKD may have resulted in an overestimation of the association [1,46].

Fifth, the results of this study cannot be generalized because the data were not obtained through random sampling from the general population. Furthermore, because only 30%–40% of the target population participated in the checkups, the generalizability of the results is further limited[16]. Furthermore, our study participants were likely healthier than the general population because people who voluntarily attend checkups have been reported to be more health-conscious and healthier[47]. This may introduce selection bias and underestimate the findings.

Sixth, competing risks that may have modified the occurrence of events (e.g., death, hospitalization) could not be assessed because the necessary data were unavailable. Finally, indicators of central and visceral fat (e.g., waist circumference, waist-to-hip ratio) were not available. Among 454 adult Koreans, elevations in these factors were more strongly associated with CKD than BMI regardless of the diabetes status[48]. In

addition, one review showed that the waist-to-height ratio is a better indicator of obesity and is associated with CKD[49]. Future studies should incorporate these variables alongside BMI to create an obesity index that better predicts CKD risk by race for both sexes without diabetes.

Conclusion

Our study of 7,489 non-diabetic Japanese adults, using the Asia-Pacific BMI classification, showed that both sexes in obesity class I had approximately 5% shorter survival to subsequent CKD onset compared with those of normal weight. Obesity class II had the shortest survival to CKD onset by point estimates in men and an almost null value in women, with all 95% CIs crossing 1. These results align with previous findings of a dose–response relationship between BMI and CKD development, particularly in men. Our study provides additional evidence suggesting that the BMI cutoff values for obesity, as defined by the conventional BMI classification, may be too high when evaluating the association between obesity and future CKD development in non-diabetic Japanese adults. Our findings may serve as a useful indicator when identifying the target population for future CKD prevention efforts.

Ethics

All data were anonymized before receipt. The Ethics Committee of Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences and Okayama University Hospital approved this study (No. K1708-040). The Ethics Committee waived the need for informed consent. Study procedures were performed in accordance with the Declaration of Helsinki and Japanese Ethical Guidelines for Medical and Biological Research Involving Human Subjects.

Acknowledgments

We are grateful to all participants of this study, Ayaka Nakatsu, Masako Matsumoto, Mayumi Kitadani, and all local government officers of Zentsuji City for their support and contribution. We thank Anahid Pinchis, BSc, MBA, Angela Morben, DVM, and Ellen Knapp, PhD, from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript.

Competing interests

This research received no external funding. Yukari Okawa is employed by Zentsuji City. Toshiharu Mitsuhashi and Toshihide Tsuda declare no potential competing interests.

Data statement

All data generated or analyzed during this study are included in this published article and its supplementary information files.

References

1. Stevens PE, Ahmed SB, Carrero JJ, et al. KDIGO 2024 Clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney International*. 2024;105(4):S117-S314. doi:10.1016/j.kint.2023.10.018

2. Betzler BK, Sultana R, Banu R, et al. Association between body mass index and chronic kidney disease in Asian populations: a participant-level meta-analysis. *Maturitas*. 2021;154:46-54. doi:10.1016/j.maturitas.2021.09.005

3. Wang J, Thornton J, Russell M, Burastero S, Heymsfield S, Pierson R. Asians have lower body mass index (BMI) but higher percent body fat than do whites: comparisons of anthropometric measurements. *The American Journal of Clinical Nutrition*. 1994;60(1):23-28. doi:10.1093/ajcn/60.1.23

4. Lee J, Min S, Oh SW, et al. Association of intraabdominal fat with the risk of incident chronic kidney disease according to body mass index among Korean adults. Magni P, ed. *PLoS ONE*. 2023;18(2):e0280766. doi:10.1371/journal.pone.0280766

5. World Health Organization Regional Office for the Western Pacific Region. *The Asia-Pacific Perspective: Redefining Obesity and Its Treatment*. Sydney: Health Communications Australia; 2000. Accessed January 20, 2025. https://iris.who.int/handle/10665/206936

6. World Health Organization. A healthy lifestyle - WHO recommendations. Accessed January 25, 2025. https://www.who.int/europe/news-room/fact-sheets/item/a-healthy-lifestyle---who-recommendations

7. Shen Y, Cai R, Sun J, et al. Diabetes mellitus as a risk factor for incident chronic kidney disease and end-stage renal disease in women compared with men: A systematic review and meta-analysis. *Endocrine*. 2017;55(1):66-76. doi:10.1007/s12020-016-1014-6

8. Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. *CJASN*. 2011;6(10):2364-2373. doi:10.2215/CJN.02180311

9. Fabrizi F, Verdesca S, Messa P, Martin P. Hepatitis C virus infection increases the risk of developing chronic kidney disease: a systematic review and meta-analysis. *Dig Dis Sci*. 2015;60(12):3801-3813. doi:10.1007/s10620-015-3801-y

10. Garofalo C, Borrelli S, Minutolo R, Chiodini P, De Nicola L, Conte G. A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population. *Kidney International*. 2017;91(5):1224-1235. doi:10.1016/j.kint.2016.12.013

11. Seidu S, Abdool M, Almaqhawi A, et al. Physical activity and risk of chronic kidney disease: systematic review and meta-analysis of 12 cohort studies involving 1,281,727 participants. *Eur J Epidemiol*. 2023;38(3):267-280. doi:10.1007/s10654-022-00961-7

12. The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. *The Lancet*. 2010;375(9733):2215-2222. doi:10.1016/S0140-6736(10)60484-9

13. The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting Glucose, and risk of cause-specific death. *N Engl J Med*. 2011;364(9):829-841. doi:10.1056/NEJMoa1008862

14. Tsujimoto T, Sairenchi T, Iso H, et al. The dose-response relationship between body mass index and the risk of incident stage ≥3 chronic kidney disease in a general Japanese population: The Ibaraki Prefectural Health Study (IPHS). *Journal of Epidemiology*. 2014;24(6):444-451. doi:10.2188/jea.JE20140028

15. Ibaraki Prefectural Health Plaza. Ibaraki Prefectural Health Study: IPHS. Accessed January 25, 2025. https://www.hsc-i.jp/05_chousa/iphs.htm

16. Zentsuji City. Zentsuji City official website. Accessed January 25, 2025. https://www.city.zentsuji.kagawa.jp

17. Okawa Y, Suzuki E, Mitsuhashi T, Tsuda T, Yorifuji T. A population-based longitudinal study on glycated hemoglobin levels and new-onset chronic kidney disease among non-diabetic Japanese adults. *Sci Rep*. 2023;13(1):13770. doi:10.1038/s41598-023-40300-8

18. Okawa Y, Mitsuhashi T. Association between blood pressure and new onset of chronic kidney disease in non-diabetic Japanese adults: a population-based longitudinal study from 1998 to 2023. *Nutrition, Metabolism and Cardiovascular Diseases*. Published online May 2024:S093947532400173X. doi:10.1016/j.numecd.2024.05.005

19. Okawa Y, Mitsuhashi T, Suzuki E. Aspartate/alanine aminotransferase ratio and development of chronic kidney disease in non-diabetic men and women: a population-based longitudinal study in Kagawa, Japan. *Clin Exp Nephrol*. Published online December 6, 2024. doi:10.1007/s10157-024-02601-8

20. Okawa Y, Mitsuhashi T. Dyslipidemia and development of chronic kidney disease in non-diabetic Japanese adults: A 26-year, community-based, longitudinal study. *Kidney and Dialysis*. 2024;4(4):246-256. doi:10.3390/kidneydial4040020

21. Ministry of Health, Labour and Welfare. Specific health examination and specific health guidance. Accessed January 25, 2025. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000161103.html

22. American Diabetes Association Professional Practice Committee, ElSayed NA, Aleppo G, et al. 2. Diagnosis and classification of diabetes: *Standards of care in diabetes—2024*. *Diabetes Care*. 2024;47(Supplement_1):S20-S42. doi:10.2337/dc24-S002

23. Matsuo S, Yasuda Y, Imai E, Horio M. Current status of estimated glomerular filtration rate (eGFR) equations for Asians and an approach to create a common eGFR equation: approach to eGFR equation for Asians. *Nephrology*. 2010;15:45-48. doi:10.1111/j.1440-1797.2010.01313.x

24. Lapedis CJ, Mariani LH, Jang BJ, Hodgin J, Hicken MT. Understanding the link between neighborhoods and kidney disease. *Kidney360*. 2020;1(8):845-854. doi:10.34067/KID.0001202019

25. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: Executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. *Hypertension*. 2018;71(6):1269-1324. doi:10.1161/HYP.0000000000000066

26. Kinoshita M, Yokote K, Arai H, et al. Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017. *J Atheroscler Thromb*. 2018;25(9):846-984. doi:10.5551/jat.GL2017

27. The Japan Diabetes Society. The Japan Diabetes Society. Accessed January 25, 2025. http://www.jds.or.jp/modules/en

28. NGSP. NGSP Home. Accessed January 25, 2025. https://ngsp.org

29. Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. *Journal of Diabetes Investigation*. 2012;3(1):39-40. doi:10.1111/j.2040-1124.2012.00207.x

30. Schoenfeld D. Partial residuals for the proportional hazards regression model. *Biometrika*. 1982;69(1):239-241. doi:10.1093/biomet/69.1.239

31. Akaike H. A new look at the statistical model identification. *IEEE Trans Automat Contr*. 1974;19(6):716-723. doi:10.1109/TAC.1974.1100705

32. Schwarz G. Estimating the dimension of a model. *Ann Statist*. 1978;6(2). doi:10.1214/aos/1176344136

33. Cleves MA, Gould W, Marchenko YV. *An Introduction to Survival Analysis Using Stata*. Revised third edition. Stata Press; 2016.

34. von Hippel PT. How many imputations do you need? A two-stage calculation using a quadratic rule. *Sociological Methods & Research*. 2020;49(3):699-718. doi:10.1177/0049124117747303

35. Young R, Johnson DR. Handling missing values in longitudinal panel data with multiple imputation. *Fam Relat*. 2015;77(1):277-294. doi:10.1111/jomf.12144

36. Westreich D, Greenland S. The Table 2 fallacy: presenting and interpreting confounder and modifier coefficients. *American Journal of Epidemiology*. 2013;177(4):292-298. doi:10.1093/aje/kws412

37. Python Software Foundation. Python. Python.org. April 5, 2023. Accessed January 25, 2025. https://www.python.org/

38. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. *Epidemiology*. 2007;18(6):805-835. doi:10.1097/EDE.0b013e3181577511

39. Tarui I, Okada E, Okada C, Saito A, Takimoto H. Trends in BMI among elderly Japanese population: findings from 1973 to 2016 Japan National Health and Nutrition Survey. *Public Health Nutr*. 2020;23(11):1907-1915. doi:10.1017/S1368980019004828

40. Hernán MA. The hazards of hazard ratios. *Epidemiology*. 2010;21(1):13-15. doi:10.1097/EDE.0b013e3181c1ea43

41. Janssen I, Heymsfield SB, Wang Z, Ross R. Skeletal muscle mass and distribution in 468 men and women aged 18–88 yr. *Journal of Applied Physiology*. 2000;89(1):81-88. doi:10.1152/jappl.2000.89.1.81

42. Nankivell BJ, Nankivell LFJ, Elder GJ, Gruenewald SM. How unmeasured muscle mass affects estimated GFR and diagnostic inaccuracy. *EClinicalMedicine*. 2020;29-30:100662. doi:10.1016/j.eclinm.2020.100662

43. Abarca-Gómez L, Abdeen ZA, Hamid ZA, et al. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement

studies in 128·9 million children, adolescents, and adults. *The Lancet*. 2017;390(10113):2627-2642. doi:10.1016/S0140-6736(17)32129-3

44. Goh VHH, Tain CF, Tong TYY, Mok HPP, Wong MT. Are BMI and other anthropometric measures appropriate as indices for obesity? A study in an Asian population. *Journal of Lipid Research*. 2004;45(10):1892-1898. doi:10.1194/jlr.M400159-JLR200

45. Chen L, Qiu B. Analysis of length-biased and partly interval-censored survival data with mismeasured covariates. *Biometrics*. Published online July 17, 2023:biom.13898. doi:10.1111/biom.13898

46. Fujii R, Pattaro C, Tsuboi Y, et al. Comparison of glomerular filtration rate estimating formulas among Japanese adults without kidney disease. *Clinical Biochemistry*. 2023;111:54-59. doi:10.1016/j.clinbiochem.2022.10.011

47. Bjerregaard AL, Maindal HT, Bruun NH, Sandbæk A. Patterns of attendance to health checks in a municipality setting: the Danish 'Check Your Health Preventive Program.' *Preventive Medicine Reports*. 2017;5:175-182. doi:10.1016/j.pmedr.2016.12.011

48. Oh H, Quan SA, Jeong JY, Jang SN, Lee JE, Kim DH. Waist circumference, not body mass index, is associated with renal function decline in Korean population: Hallym Aging Study. Vliegenthart R, ed. *PLoS ONE*. 2013;8(3):e59071. doi:10.1371/journal.pone.0059071

49. Liu L, Wang Y, Zhang W, Chang W, Jin Y, Yao Y. Waist height ratio predicts chronic kidney disease: a systematic review and meta-analysis, 1998–2019. *Arch Public Health*. 2019;77(1):55. doi:10.1186/s13690-019-0379-4

Figures and Tables



Figure 1. Participant flow chart of the study cohort.



Number at risk

Underweight	166	87	45	25	2	0
Normal weight	1308	731	397	189	56	1
Overweight	762	455	229	126	22	0
Obesity class I	784	430	206	81	26	0
Obesity class II	78	31	15	12	4	0

Number at risk

Underweight	332	200	110	72	33	0
Normal weight	2150	1295	762	438	159	1
Overweight	882	533	303	176	60	0
Obesity class I	890	486	258	133	43	0
Obesity class II	137	86	37	23	6	0

Figure 2. Kaplan–Meier survival estimates by Asia-Pacific body mass index classification for men and women.

Table 1. Descriptive statistics of all observations stratified by the Asia-Pacific BMI classification among 3,098 non-diabetic Japanese male citizens of Zentsuji City (1998–2023)

	Asia-Pacific BMI classification																	
	< 18.5 kg/m^2 Underweight			18.5–22.9 kg/m^2 Normal weight			23.0–24.9 kg/m^2 Overweight			25.0–29.9 kg/m^2 Obesity class I			≥ 30.0 kg/m^2 Obesity class II			Total		
	Failure	PY	IR*	Failure	PY	IR*	Failure	PY	IR*	Failure	PY	IR*	Failure	PY	IR*	Failure	PY	IR*
Time at risk																		
Total		1,145.5			9,941.5			5,877.1			5,532.7			468.8			22,965.6	
Minimum		0.71			0.40			0.46			0.34			0.60			0.34	
Maximum		20.4			24.5			23.2			24.3			22.2			24.5	
Mean		4.44			6.05			4.82			5.23			4.15			7.41	
Median		2.91			4.19			3.16			3.89			2.99			5.99	
Failure/IR*	40		34.9	438		44.1	272		46.3	287		51.9	22		46.9	1,059		46.1
Variables																		
Age category in years																		
34–59	2	241.9	8.3	35	2,327.5	15.0	25	1,671.4	15.0	39	1,838.7	21.2	4	223.8	17.9	105	6,303.3	16.7
60–69	11	353.9	31.1	168	3,763.0	44.6	107	2,140.8	50.0	114	1,994.6	57.2	11	137.3	80.1	411	8,389.5	49.0
70–100	27	549.7	49.1	235	3,851.0	61.0	140	2,064.9	67.8	134	1,699.5	78.8	7	107.7	65.0	543	8,272.8	65.6
Self-reported alcohol intake																		
Nondrinker	19.9	546.2	36.4	170.7	3,732.4	45.7	114.1	2,127.5	53.6	108.4	1,972.1	55.0	8.5	209.4	40.6	421.6	8,587.6	49.1
Drinker	20.2	599.3	33.6	267.3	6,209.2	43.0	157.9	3,749.6	42.1	178.6	3,560.7	50.2	13.5	259.3	52.1	637.4	14,378.0	44.3
Self-reported smoker status																		
Nonsmoker	25.1	706.5	35.6	299.2	6,659.9	44.9	205.4	4,200.7	48.9	225.5	3,916.6	57.6	18.6	340.3	54.6	773.8	15,823.9	48.9
Smoker	14.9	439.1	34.0	138.8	3,281.7	42.3	66.6	1,676.3	39.7	61.6	1,616.2	38.1	3.4	128.5	26.7	285.3	7,141.7	39.9
Hypertension†																		
No	22.0	647.0	34.0	190.0	5,100.0	37.3	103.0	2,426.9	42.4	85.0	1,759.7	48.3	3.0	128.5	23.3	403.0	10,062.0	40.1
Yes	18.0	498.5	36.1	248.0	4,841.6	51.2	169.0	3,450.2	49.0	202.0	3,773.0	53.5	19.0	340.3	55.8	656.0	12,903.6	50.8
Dyslipidemia‡																		
No	24.0	693.4	34.6	196.4	4,983.6	39.4	99.5	2,316.5	42.9	93.8	1,797.3	52.2	5.8	128.5	44.8	419.4	9,919.4	42.3
Yes	16.0	452.1	35.5	241.6	4,957.9	48.7	172.5	3,560.5	48.5	193.2	3,735.4	51.7	16.3	340.2	47.8	639.6	13,046.2	49.0
Residential district																		
East	8.1	208.2	39.0	103.9	1,986.6	52.3	53.0	1,329.6	39.9	55.0	1,071.1	51.4	3.2	63.1	50.1	223.2	4,658.7	47.9
Tatsukawa	4.2	142.7	29.1	60.5	1,755.3	34.4	40.0	976.3	41.0	44.1	893.3	49.4	3.2	107.3	30.0	152.0	3,874.9	39.2
Central	7.2	162.4	44.0	64.0	1,246.0	51.4	30.0	677.8	44.3	34.7	666.1	52.0	1.2	78.2	14.6	137.0	2,830.4	48.4
Fudeoka	2.1	116.7	18.2	38.9	1,180.6	33.0	29.0	702.3	41.3	42.9	769.5	55.8	9.2	90.4	101.5	122.2	2,859.5	42.7
South	5.2	176.5	29.2	49.1	1,120.7	43.8	43.0	770.6	55.8	30.5	622.7	49.0	3.1	63.8	48.5	130.9	2,754.3	47.5
West	5.0	160.2	31.2	53.6	999.4	53.6	36.0	542.7	66.3	34.6	646.0	53.5	0.0	17.4	1.0	129.2	2,365.7	54.6
Yoshiwara	5.2	94.8	54.3	43.7	1,050.5	41.6	28.0	608.8	46.0	28.7	456.2	63.0	1.1	25.5	41.7	106.7	2,235.9	47.7
Yogita	3.2	84.0	37.5	24.4	602.5	40.4	13.0	268.9	48.3	16.5	407.7	40.3	1.1	23.1	46.0	58.0	1,386.3	41.9
HbA1c values, %																		
Mean (SD)	5.39	(0.37)		5.40	(0.40)		5.43	(0.42)		5.49	(0.42)		5.59	(0.40)		5.43	(0.41)	

Abbreviations: BMI, body mass index; HbA1c, hemoglobin A1c; IR, incidence rate; PY, person-years; SD, standard deviation.

Results for multiple imputed variables (self-reported alcohol intake, self-reported smoking status, hypertension†, dyslipidemia‡, and residential district) are averaged over 40 imputations.

*Incidence rate is reported per 1,000 person-years.

†Hypertension is defined as systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥80 mmHg.

‡Dyslipidemia is defined as serum low density lipoprotein cholesterol ≥140 mg/dL, serum high density lipoprotein cholesterol <40 mg/dL, and/or serum triglycerides ≥150 mg/dL.

Table 2. Descriptive statistics of all observations stratified by the Asia-Pacific BMI classification among 4,391 non-diabetic Japanese female citizens of Zentsuji City (1998–2023)

	Asia-Pacific BMI classification																	
	< 18.5 kg/m^2 Underweight			18.5–22.9 kg/m^2 Normal weight			23.0–24.9 kg/m^2 Overweight			25.0–29.9 kg/m^2 Obesity class I			≥ 30.0 kg/m^2 Obesity class II			Total		
	Failure	PY	IR*	Failure	PY	IR*	Failure	PY	IR*	Failure	PY	IR*	Failure	PY	IR*	Failure	PY	IR*
Time at risk																		
Total		2,804.2			18,306.5			7,424.3			6,627.6			1,055.4			36,218.0	
Minimum		0.63			0.48			0.48			0.53			0.80			0.48	
Maximum		24.3			24.7			22.8			24.3			20.3			24.7	
Mean		4.95			7.00			5.09			5.49			4.91			8.25	
Median		3.05			5.05			3.63			3.87			3.10			6.83	
Failure/IR*	106		37.8	697		38.1	307		41.4	371		56.0	45		42.6	1,526		42.1
Variables																		
Age category in years																		
34–59	23	1,137.7	20.2	187	7,825.2	23.9	70	2,392.4	29.3	73	1,980.3	36.9	9	436.8	20.6	362.0	13,772.4	26.3
60–69	23	761.2	30.2	199	5,690.4	35.0	93	2,816.1	33.0	117	2,455.0	47.7	12	300.7	39.9	444.0	12,023.4	36.9
70–100	60	905.2	66.3	311	4,790.9	64.9	144	2,215.9	65.0	181	2,192.3	82.6	24	317.9	75.5	720.0	10,422.2	69.1
Self-reported alcohol intake																		
Nondrinker	86.2	2,085.0	41.3	532.3	13,267.3	40.1	238.1	5,518.0	43.1	303.4	5,153.4	58.9	39.4	819.4	48.0	1,199.3	26,843.1	44.7
Drinker	19.9	719.1	27.6	164.7	5,039.3	32.7	68.9	1,906.4	36.2	67.6	1,474.2	45.8	5.7	236.0	23.9	326.7	9,375.0	34.8
Self-reported smoker status																		
Nonsmoker	102.6	2,568.8	39.9	668.3	17,266.9	38.7	297.0	7,090.5	41.9	362.5	6,334.9	57.2	43.8	991.1	44.2	1,474.3	34,252.2	43.0
Smoker	3.4	235.4	14.5	28.7	1,039.7	27.6	10.0	333.8	30.0	8.5	292.8	29.1	1.2	64.3	18.4	51.8	1,965.9	26.3
Hypertension*																		
No	53.0	1,950.8	27.2	330.0	10,753.6	30.7	110.0	3,377.2	32.6	113.0	2,314.1	48.8	11.0	243.3	45.2	617.0	18,639.0	33.1
Yes	53.0	853.3	62.1	367.0	7,553.0	48.6	197.0	4,047.2	48.7	258.0	4,313.5	59.8	34.0	812.0	41.9	909.0	17,579.0	51.7
Dyslipidemia†																		
No	64.6	1,776.0	36.4	330.1	9,347.6	35.3	119.3	3,067.8	38.9	126.4	2,521.8	50.1	16.5	404.0	40.8	656.9	17,117.1	38.4
Yes	41.5	1,028.1	40.4	366.9	8,959.0	41.0	187.7	4,356.6	43.1	244.6	4,105.8	59.6	28.5	651.4	43.8	869.1	19,100.9	45.5
Residential district																		
East	22.0	508.0	43.3	132.8	3,621.6	36.7	57.8	1,429.9	40.4	76.7	1,447.1	53.0	8.0	215.2	37.2	297.3	7,221.8	41.2
Tatsukawa	15.0	557.7	26.9	101.0	3,329.9	30.3	57.0	1,223.3	46.6	52.6	1,102.7	47.7	7.0	170.3	41.1	232.6	6,383.9	36.4
Central	21.0	452.7	46.4	106.5	2,508.4	42.5	43.0	950.6	45.2	51.3	874.0	58.7	11.0	157.2	70.0	232.8	4,943.0	47.1
Fudeoka	10.0	278.3	35.9	93.4	2,344.1	39.8	31.8	954.4	33.3	49.5	858.1	57.7	3.0	146.8	20.4	187.7	4,581.7	41.0
South	11.0	363.7	30.3	70.1	1,917.1	36.6	31.8	808.7	39.3	39.5	702.6	56.3	4.0	109.7	36.5	156.4	3,901.8	40.1
West	6.0	292.9	20.5	69.0	1,903.6	36.3	38.7	791.4	48.8	43.4	586.3	74.1	5.0	111.0	45.1	162.1	3,685.2	44.0
Yoshiwara	10.0	192.0	52.1	80.8	1,773.7	45.5	28.6	819.1	34.9	35.6	591.0	60.2	4.0	96.0	41.7	159.0	3,471.8	45.8
Yogita	11.0	158.7	69.3	43.5	908.1	47.8	18.4	447.0	41.1	22.4	465.8	48.0	3.0	49.3	61.0	98.2	2,029.0	48.4
HbA1c values, %																		
Mean (SD)	5.45	(0.34)		5.45	(0.38)		5.50	(0.39)		5.53	(0.39)		5.54	(0.37)		5.48	(0.38)	

Abbreviations: BMI, body mass index; HbA1c, hemoglobin A1c; IR, incidence rate; PY, person-years; SD, standard deviation.

Results for multiple imputed variables (self-reported alcohol intake, self-reported smoking status, hypertension*, dyslipidemia†, and residential district) are averaged over 40 imputations.

*Incidence rate is reported per 1,000 person-years.

†Hypertension is defined as systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥80 mmHg.

‡Dyslipidemia is defined as serum low density lipoprotein cholesterol ≥140 mg/dL, serum high density lipoprotein cholesterol <40 mg/dL, and/or serum triglycerides ≥150 mg/dL.

Table 3. New onset of chronic kidney disease defined by the Asia-Pacific BMI classification in non-diabetic Japanese citizens of Zentsuji City (1998–2023)

					Crude	Model 1	Model 2	Model 3
Asia-Pacific BMI classification		PY	Failure	IR‡	TR (95% CI)	aTR (95% CI)	aTR (95% CI)	aTR (95% CI)
Men (n=3,098)								
<18.5 kg/m^2	Underweight	1,145.5	40	34.9	1.08 (1.00–1.16)	1.08 (0.99–1.17)	1.08 (0.99–1.17)	1.08 (1.00–1.17)
18.5–22.9 kg/m^2 (reference)	Normal weight	9,941.5	438	44.1	1.00	1.00	1.00	1.00
23.0–24.9 kg/m^2	Overweight	5,877.1	272	46.3	0.97 (0.94–1.01)	0.97 (0.94–1.00)	0.97 (0.93–1.00)	0.97 (0.94–1.01)
25.0–29.9 kg/m^2	Obesity class I	5,532.7	287	51.9	0.94 (0.90–0.97)	0.93 (0.90–0.97)	0.93 (0.90–0.97)	0.94 (0.90–0.98)
≥30.0 kg/m^2	Obesity class II	468.8	22	46.9	0.92 (0.82–1.02)	0.92 (0.82–1.02)	0.92 (0.82–1.02)	0.92 (0.82–1.02)
					Crude	Model 1	Model 2	Model 3
Asia-Pacific BMI classification		PY	Failure	IR‡	TR (95% CI)	aTR (95% CI)	aTR (95% CI)	aTR (95% CI)
Women (n=4,391)								
<18.5 kg/m^2	Underweight	2,804.2	106	37.8	1.02 (0.97–1.06)	1.02 (0.98–1.06)	1.02 (0.97–1.06)	1.01 (0.96–1.05)
18.5–22.9 kg/m^2 (reference)	Normal weight	18,306.5	697	38.1	1.00	1.00	1.00	1.00
23.0–24.9 kg/m^2	Overweight	7,424.3	307	41.4	0.99 (0.96–1.02)	0.99 (0.96–1.02)	0.99 (0.96–1.02)	1.00 (0.97–1.03)
25.0–29.9 kg/m^2	Obesity class I	6,627.6	371	56.0	0.94 (0.92–0.97)	0.95 (0.92–0.97)	0.95 (0.92–0.97)	0.95 (0.93–0.98)
≥30.0 kg/m^2	Obesity class II	1,055.4	45	42.6	0.97 (0.91–1.03)	0.97 (0.91–1.03)	0.97 (0.91–1.03)	0.98 (0.92–1.05)

Abbreviations: aTR, adjusted time ratio; BMI, body mass index; CI, confidence interval; HbA1c, hemoglobin A1c; IR, incidence rate; PY, person-years; TR, time ratio.

*Hypertension is defined as systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥80 mmHg.

†Dyslipidemia is defined as serum low-density lipoprotein cholesterol ≥140 mg/dL, serum high-density lipoprotein cholesterol <40 mg/dL, and/or serum triglycerides ≥150 mg/dL.

‡Incidence rate is reported per 1,000 person-years.

Multiple imputed variables: hypertension*, dyslipidemia†, self-reported alcohol intake, self-reported smoking status, and residential district.

Model 1: Adjusted for age category (34–59[reference]/60–69/70–100).

Model 2: Adjusted for the variable of Model 1, self-reported alcohol intake (non- or seldom-drinker [reference]/drinker), and self-reported smoking status (non- or ex-smoker [reference]/smoker).

Model 3: Adjusted for all variables of Model 2, hypertension* (no[reference]/yes), dyslipidemia† (no[reference]/yes), HbA1c values, and residential district (East[reference]/Tatsukawa/Central/Fudeoka/South/West/Yoshiwara/Yogita).